Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Restricted access

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection.

  • 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:730.

  • 2.

    Eheman C, Henley SJ, Ballard-Barbash R. Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012;118:23382366.

    • Search Google Scholar
    • Export Citation
  • 3.

    Simard EP, Ward EM, Siegel R, Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62:118128.

    • Search Google Scholar
    • Export Citation
  • 4.

    Smith BD, Smith GL, Hurria A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009;27:27582765.

    • Search Google Scholar
    • Export Citation
  • 5.

    StatBite. U.S. pancreatic cancer rates. J Natl Cancer Inst 2010;102:1822.

  • 6.

    Worni M, Guller U, White RR. Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas 2013;42:11571163.

    • Search Google Scholar
    • Export Citation
  • 7.

    Chari ST, Leibson CL, Rabe KG. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504511.

    • Search Google Scholar
    • Export Citation
  • 8.

    Gupta S, Vittinghoff E, Bertenthal D. New-onset diabetes and pancreatic cancer. Clin Gastroenterol Hepatol 2006;4:13661372; quiz 1301.

  • 9.

    Raghavan SR, Ballehaninna UK, Chamberlain RS. The impact of perioperative blood glucose levels on pancreatic cancer prognosis and surgical outcomes: an evidence-based review. Pancreas 2013;42:12101217.

    • Search Google Scholar
    • Export Citation
  • 10.

    Canto MI, Harinck F, Hruban RH. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut 2013;62:339347.

    • Search Google Scholar
    • Export Citation
  • 11.

    Callery MP, Chang KJ, Fishman EK. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009;16:17271733.

    • Search Google Scholar
    • Export Citation
  • 12.

    Al-Hawary MM, Francis IR, Chari ST. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Gastroenterology 2014;146:291304.e291.

    • Search Google Scholar
    • Export Citation
  • 13.

    Horton KM, Fishman EK. Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am 2002;40:12631272.

  • 14.

    House MG, Yeo CJ, Cameron JL. Predicting resectability of periampullary cancer with three-dimensional computed tomography. J Gastrointest Surg 2004;8:280288.

    • Search Google Scholar
    • Export Citation
  • 15.

    Klauss M, Schobinger M, Wolf I. Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results. World J Gastroenterol 2009;15:58275832.

    • Search Google Scholar
    • Export Citation
  • 16.

    McNulty NJ, Francis IR, Platt JF. Multi-detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology 2001;220:97102.

    • Search Google Scholar
    • Export Citation
  • 17.

    Schima W, Ba-Ssalamah A, Goetzinger P. State-of-the-art magnetic resonance imaging of pancreatic cancer. Top Magn Reson Imaging 2007;18:421429.

    • Search Google Scholar
    • Export Citation
  • 18.

    Vachiranubhap B, Kim YH, Balci NC, Semelka RC. Magnetic resonance imaging of adenocarcinoma of the pancreas. Top Magn Reson Imaging 2009;20:39.

    • Search Google Scholar
    • Export Citation
  • 19.

    Li JH, He R, Li YM. Endoscopic ultrasonography for tumor node staging and vascular invasion in pancreatic cancer: a meta-analysis. Dig Surg 2014;31:297305.

    • Search Google Scholar
    • Export Citation
  • 20.

    Agarwal B, Abu-Hamda E, Molke KL. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 2004;99:844850.

    • Search Google Scholar
    • Export Citation
  • 21.

    Deerenberg EB, Poley JW, Hermans JJ. Role of endoscopic ultrasonography in patients suspected of pancreatic cancer with negative helical MDCT scan. Dig Surg 2011;28:398403.

    • Search Google Scholar
    • Export Citation
  • 22.

    Nawaz H, Fan CY, Kloke J. Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP 2013;14:484497.

    • Search Google Scholar
    • Export Citation
  • 23.

    Wang W, Shpaner A, Krishna SG. Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT. Gastrointest Endosc 2013;78:7380.

    • Search Google Scholar
    • Export Citation
  • 24.

    Pavey DA, Gress FG. The role of EUS-guided FNA for the evaluation of biliary strictures. Gastrointest Endosc 2006;64:334337.

  • 25.

    Dolejs S, Zarzaur BL, Zyromski NJ. Does hyperbilirubinemia contribute to adverse patient outcomes following pancreatoduodenectomy? J Gastrointest Surg 2017;21:647656.

    • Search Google Scholar
    • Export Citation
  • 26.

    Mezhir JJ, Brennan MF, Baser RE. A matched case-control study of preoperative biliary drainage in patients with pancreatic adenocarcinoma: routine drainage is not justified. J Gastrointest Surg 2009;13:21632169.

    • Search Google Scholar
    • Export Citation
  • 27.

    van der Gaag NA, Rauws EA, van Eijck CH. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010;362:129137.

    • Search Google Scholar
    • Export Citation
  • 28.

    Ahmed SI, Bochkarev V, Oleynikov D, Sasson AR. Patients with pancreatic adenocarcinoma benefit from staging laparoscopy. J Laparoendosc Adv Surg Tech A 2006;16:458463.

    • Search Google Scholar
    • Export Citation
  • 29.

    Allen VB, Gurusamy KS, Takwoingi Y. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database Syst Rev 2013;11:CD009323.

    • Search Google Scholar
    • Export Citation
  • 30.

    Warshaw AL, Gu ZY, Wittenberg J, Waltman AC. Preoperative staging and assessment of resectability of pancreatic cancer. Arch Surg 1990;125:230233.

    • Search Google Scholar
    • Export Citation
  • 31.

    Brugge WR, De Witt J, Klapman JB. Techniques for cytologic sampling of pancreatic and bile duct lesions: the Papanicolaou Society of Cytopathology guidelines. Cytojournal 2014;11(Suppl 1):2.

    • Search Google Scholar
    • Export Citation
  • 32.

    Micames C, Jowell PS, White R. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 2003;58:690695.

    • Search Google Scholar
    • Export Citation
  • 33.

    Okasha HH, Naga MI, Esmat S. Endoscopic ultrasound-guided fine needle aspiration versus percutaneous ultrasound-guided fine needle aspiration in diagnosis of focal pancreatic masses. Endosc Ultrasound 2013;2:190193.

    • Search Google Scholar
    • Export Citation
  • 34.

    Layfield LJ, Dodd L, Factor R, Schmidt RL. Malignancy risk associated with diagnostic categories defined by the Papanicolaou Society of Cytopathology pancreaticobiliary guidelines. Cancer Cytopathol 2014;122:420427.

    • Search Google Scholar
    • Export Citation
  • 35.

    Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol 2014;35:74597465.

  • 36.

    Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 2012;3:105119.

    • Search Google Scholar
    • Export Citation
  • 37.

    Mann DV, Edwards R, Ho S. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474479.

    • Search Google Scholar
    • Export Citation
  • 38.

    Marrelli D, Caruso S, Pedrazzani C. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009;198:333339.

    • Search Google Scholar
    • Export Citation
  • 39.

    Hartwig W, Strobel O, Hinz U. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 2013;20:21882196.

    • Search Google Scholar
    • Export Citation
  • 40.

    Kim YC, Kim HJ, Park JH. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma? J Gastroenterol Hepatol 2009;24:18691875.

    • Search Google Scholar
    • Export Citation
  • 41.

    Kondo N, Murakami Y, Uemura K. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010;17:23212329.

    • Search Google Scholar
    • Export Citation
  • 42.

    Burris HA III, Moore MJ, Andersen J. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:24032413.

    • Search Google Scholar
    • Export Citation
  • 43.

    Oettle H, Post S, Neuhaus P. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297:267277.

    • Search Google Scholar
    • Export Citation
  • 44.

    Oettle H, Neuhaus P, Hochhaus A. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013;310:14731481.

    • Search Google Scholar
    • Export Citation
  • 45.

    Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2’,2’-difluorodeoxycytidine 5’-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991;27:258262.

    • Search Google Scholar
    • Export Citation
  • 46.

    Poplin E, Feng Y, Berlin J. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:37783785.

    • Search Google Scholar
    • Export Citation
  • 47.

    Demols A, Peeters M, Polus M. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481485.

    • Search Google Scholar
    • Export Citation
  • 48.

    Fine RL, Fogelman DR, Schreibman SM. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol 2008;61:167175.

    • Search Google Scholar
    • Export Citation
  • 49.

    Ciliberto D, Botta C, Correale P. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013;49:593603.

    • Search Google Scholar
    • Export Citation
  • 50.

    Sun C, Ansari D, Andersson R, Wu DQ. Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? World J Gastroenterol 2012;18:49444958.

    • Search Google Scholar
    • Export Citation
  • 51.

    Heinemann V, Boeck S, Hinke A. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82.

    • Search Google Scholar
    • Export Citation
  • 52.

    Heinemann V, Quietzsch D, Gieseler F. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:39463952.

    • Search Google Scholar
    • Export Citation
  • 53.

    Herrmann R, Bodoky G, Ruhstaller T. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:22122217.

    • Search Google Scholar
    • Export Citation
  • 54.

    Von Hoff DD, Ramanathan RK, Borad MJ. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011;29:45484554.

    • Search Google Scholar
    • Export Citation
  • 55.

    Von Hoff DD, Ervin T, Arena FP. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:16911703.

    • Search Google Scholar
    • Export Citation
  • 56.

    Chiorean EG, Von Hoff DD, Reni M. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol 2016;27:654660.

    • Search Google Scholar
    • Export Citation
  • 57.

    Goldstein D, Von Hoff DD, Moore M. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: a subset analysis from a randomised phase III trial (MPACT). Eur J Cancer 2016;52:8591.

    • Search Google Scholar
    • Export Citation
  • 58.

    Goldstein D, El-Maraghi RH, Hammel P. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015;107:pii: dju413.

    • Search Google Scholar
    • Export Citation
  • 59.

    Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996;32a:11351141.

    • Search Google Scholar
    • Export Citation
  • 60.

    Ma C, Bandukwala S, Burman D. Interconversion of three measures of performance status: an empirical analysis. Eur J Cancer 2010;46:31753183.

    • Search Google Scholar
    • Export Citation
  • 61.

    Moore MJ, Goldstein D, Hamm J. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:19601966.

    • Search Google Scholar
    • Export Citation
  • 62.

    Colucci G, Giuliani F, Gebbia V. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902910.

    • Search Google Scholar
    • Export Citation
  • 63.

    Colucci G, Labianca R, Di Costanzo F. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:16451651.

    • Search Google Scholar
    • Export Citation
  • 64.

    Golan T, Kanji ZS, Epelbaum R. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111:11321138.

    • Search Google Scholar
    • Export Citation
  • 65.

    Majdak EJ, Debniak J, Milczek T. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 2005;104:10041012.

    • Search Google Scholar
    • Export Citation
  • 66.

    Stefansson OA, Jonasson JG, Johannsson OT. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009;11:R47.

    • Search Google Scholar
    • Export Citation
  • 67.

    Ferrone CR, Levine DA, Tang LH. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433438.

  • 68.

    Oliver GR, Sugar E, Laheru D, Diaz LA. Family history of cancer and sensitivity to platinum chemotherapy in pancreatic adenocarcinoma [abstract]. Presented at the 2010 Gastrointestinal Cancers Symposium; January 22–24, 2010; Orlando, FL. Abstract 180.

    • Search Google Scholar
    • Export Citation
  • 69.

    Cunningham D, Chau I, Stocken DD. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27:55135518.

    • Search Google Scholar
    • Export Citation
  • 70.

    Li Q, Yan H, Liu W. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials. PLoS One 2014;9:e104346.

    • Search Google Scholar
    • Export Citation
  • 71.

    Conroy T, Desseigne F, Ychou M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:18171825.

  • 72.

    Peixoto RD, Ho M, Renouf DJ. Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol, in press.

    • Search Google Scholar
    • Export Citation
  • 73.

    Conroy T, Paillot B, Francois E. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer—a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005;23:12281236.

    • Search Google Scholar
    • Export Citation
  • 74.

    Ychou M, Desseigne F, Guimbaud R. Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial [abstract]. J Clin Oncol 2007;25(Suppl):Abstract 4516.

    • Search Google Scholar
    • Export Citation
  • 75.

    Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013;31:2329.

    • Search Google Scholar
    • Export Citation
  • 76.

    Lowery MA, Yu KH, Adel NG. Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC) [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 4057.

    • Search Google Scholar
    • Export Citation
  • 77.

    Stein SM, James ES, Deng Y. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 2016;114:809812.

    • Search Google Scholar
    • Export Citation
  • 78.

    Boeck S, Vehling-Kaiser U, Waldschmidt D. Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’. Anticancer Drugs 2010;21:94100.

    • Search Google Scholar
    • Export Citation
  • 79.

    Cartwright TH, Cohn A, Varkey JA. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002;20:160164.

    • Search Google Scholar
    • Export Citation
  • 80.

    Pelzer U, Schwaner I, Stieler J. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011;47:16761681.

    • Search Google Scholar
    • Export Citation
  • 81.

    Xiong HQ, Varadhachary GR, Blais JC. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008;113:20462052.

    • Search Google Scholar
    • Export Citation
  • 82.

    Rahma OE, Duffy A, Liewehr DJ. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 2013;24:19721979.

    • Search Google Scholar
    • Export Citation
  • 83.

    Maisey N, Chau I, Cunningham D. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 2002;20:31303136.

    • Search Google Scholar
    • Export Citation
  • 84.

    Chiorean EG, Von Hoff DD, Tabernero J. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer 2016;115:e13.

    • Search Google Scholar
    • Export Citation
  • 85.

    Pelzer U, Kubica K, Stieler J. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study [abstract]. J Clin Oncol 2008;26(Suppl):Abstract 4508.

    • Search Google Scholar
    • Export Citation
  • 86.

    Saif MW. New developments in the treatment of pancreatic cancer. Highlights from the “44th ASCO Annual Meeting”. Chicago, IL, USA. May 30 - June 3, 2008. JOP 2008;9:391397.

    • Search Google Scholar
    • Export Citation
  • 87.

    Oettle H, Riess H, Stieler JM. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 2014;32:24232429.

    • Search Google Scholar
    • Export Citation
  • 88.

    Gill S, Ko YJ, Cripps C. PANCREOX: a randomized phase III study of 5-fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy [published online ahead of print September 12, 2016]. J Clin Oncol, in press.

    • Search Google Scholar
    • Export Citation
  • 89.

    Uccello M, Moschetta M, Arkenau HT. Second-line combination therapies in pancreatic cancer: where are we now? J Clin Oncol 2017;35:13701371.

  • 90.

    Wang-Gillam A, Li CP, Bodoky G. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016;387:545557.

    • Search Google Scholar
    • Export Citation
  • 91.

    Wang-Gillam A, Li CP, Bodoky G. Updated overall survival (OS) analysis of NAPOLI-1: phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 4126.

    • Search Google Scholar
    • Export Citation
  • 92.

    Neoptolemos JP, Stocken DD, Friess H. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:12001210.

    • Search Google Scholar
    • Export Citation
  • 93.

    Crane CH, Ben-Josef E, Small W. Chemotherapy for pancreatic cancer. N Engl J Med 2004;350:27132715.

  • 94.

    Koshy MC, Landry JC, Cavanaugh SX. A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 2005;61:965966.

  • 95.

    Morris SL, Beasley M, Leslie M. Chemotherapy for pancreatic cancer. N Engl J Med 2004;350:27132715; author reply 2713–2715.

  • 96.

    Ren F, Xu YC, Wang HX. Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma: continue or stop? Pancreatology 2012;12:162169.

    • Search Google Scholar
    • Export Citation
  • 97.

    Liao WC, Chien KL, Lin YL. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol 2013;14:10951103.

    • Search Google Scholar
    • Export Citation
  • 98.

    Kooby DA, Gillespie TW, Liu Y. Impact of adjuvant radiotherapy on survival after pancreatic cancer resection: an appraisal of data from the National Cancer Data Base. Ann Surg Oncol 2013;20:36343642.

    • Search Google Scholar
    • Export Citation
  • 99.

    Morganti AG, Falconi M, van Stiphout RG. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. Int J Radiat Oncol Biol Phys 2014;90:911917.

    • Search Google Scholar
    • Export Citation
  • 100.

    Neoptolemos JP, Stocken DD, Dunn JA. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758768.

    • Search Google Scholar
    • Export Citation
  • 101.

    Corsini MM, Miller RC, Haddock MG. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol 2008;26:35113516.

    • Search Google Scholar
    • Export Citation
  • 102.

    Hsu CC, Herman JM, Corsini MM. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17:981990.

    • Search Google Scholar
    • Export Citation
  • 103.

    Butturini G, Stocken DD, Wente MN. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008;143:7583; discussion 83.

    • Search Google Scholar
    • Export Citation
  • 104.

    Crane CH, Abbruzzese JL, Evans DB. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:12931302.

    • Search Google Scholar
    • Export Citation
  • 105.

    Huang J, Robertson JM, Margolis J. Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer. Radiother Oncol 2011;99:114119.

    • Search Google Scholar
    • Export Citation
  • 106.

    Murphy JD, Adusumilli S, Griffith KA. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:801808.

    • Search Google Scholar
    • Export Citation
  • 107.

    Zhu CP, Shi J, Chen YX. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol 2011;99:108113.

    • Search Google Scholar
    • Export Citation
  • 108.

    Mukherjee S, Hurt CN, Bridgewater J. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013;14:317326.

    • Search Google Scholar
    • Export Citation
  • 109.

    Hurt CN, Mukherjee S, Bridgewater J. Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2015;93:810818.

    • Search Google Scholar
    • Export Citation
  • 110.

    Loehrer PJ Sr, Feng Y, Cardenes H. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011;29:41054112.

    • Search Google Scholar
    • Export Citation
  • 111.

    Philip PA. Locally advanced pancreatic cancer: where should we go from here? J Clin Oncol 2011;29:40664068.

  • 112.

    Chauffert B, Mornex F, Bonnetain F. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19:15921599.

    • Search Google Scholar
    • Export Citation
  • 113.

    Blackstock AW, Tepper JE, Niedwiecki D. Cancer and Leukemia Group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 2003;34:107116.

    • Search Google Scholar
    • Export Citation
  • 114.

    Huguet F, Andre T, Hammel P. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326331.

    • Search Google Scholar
    • Export Citation
  • 115.

    Huguet F, Girard N, Guerche CS. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009;27:22692277.

    • Search Google Scholar
    • Export Citation
  • 116.

    Krishnan S, Rana V, Janjan NA. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007;110:4755.

    • Search Google Scholar
    • Export Citation
  • 117.

    Hammel P, Huguet F, van Laethem JL. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 2016;315:18441853.

    • Search Google Scholar
    • Export Citation
  • 118.

    Herman JM, Chang DT, Goodman KA. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer 2015;121:11281137.

    • Search Google Scholar
    • Export Citation
  • 119.

    Schellenberg D, Kim J, Christman-Skieller C. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2011;81:181188.

    • Search Google Scholar
    • Export Citation
  • 120.

    Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004;363:10491057.

  • 121.

    Neoptolemos JP, Stocken DD, Bassi C. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:10731081.

    • Search Google Scholar
    • Export Citation
  • 122.

    Regine WF, Winter KA, Abrams RA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:10191026.

    • Search Google Scholar
    • Export Citation
  • 123.

    Neoptolemos JP, Palmer DH, Ghaneh P. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:10111024.

    • Search Google Scholar
    • Export Citation
  • 124.

    Allison DC, Piantadosi S, Hruban RH. DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma. J Surg Oncol 1998;67:151159.

    • Search Google Scholar
    • Export Citation
  • 125.

    Howard TJ, Krug JE, Yu J. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg 2006;10:13381345.

    • Search Google Scholar
    • Export Citation
  • 126.

    Sohn TA, Yeo CJ, Cameron JL. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567579.

    • Search Google Scholar
    • Export Citation
  • 127.

    Abrams RA, Lowy AM, O'Reilly EM. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol 2009;16:17511756.

    • Search Google Scholar
    • Export Citation
  • 128.

    Katz MH, Marsh R, Herman JM. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol 2013;20:27872795.

    • Search Google Scholar
    • Export Citation
  • 129.

    Talamonti M. Borderline resectable pancreatic cancer: a new classification for an old challenge. Ann Surg Oncol 2006;13:10191020.

  • 130.

    Varadhachary GR, Tamm EP, Abbruzzese JL. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006;13:10351046.

    • Search Google Scholar
    • Export Citation
  • 131.

    Gumbs AA, Rodriguez Rivera AM. Laparoscopic pancreatoduodenectomy: a review of 285 published cases. Ann Surg Oncol 2011;18:13351341.

  • 132.

    Venkat R, Edil BH, Schulick RD. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg 2012;255:10481059.

    • Search Google Scholar
    • Export Citation
  • 133.

    Shrikhande SV, Barreto SG. Extended pancreatic resections and lymphadenectomy: an appraisal of the current evidence. World J Gastrointest Surg 2010;2:3946.

    • Search Google Scholar
    • Export Citation
  • 134.

    Cordera F, Arciero CA, Li T. Significance of common hepatic artery lymph node metastases during pancreaticoduodenectomy for pancreatic head adenocarcinoma. Ann Surg Oncol 2007;14:23302336.

    • Search Google Scholar
    • Export Citation
  • 135.

    Shimada K, Sakamoto Y, Sano T, Kosuge T. The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma. J Am Coll Surg 2006;203:345352.

    • Search Google Scholar
    • Export Citation
  • 136.

    Gundry SR, Strodel WE, Knol JA. Efficacy of preoperative biliary tract decompression in patients with obstructive jaundice. Arch Surg 1984;119:703708.

    • Search Google Scholar
    • Export Citation
  • 137.

    Hatfield AR, Tobias R, Terblanche J. Preoperative external biliary drainage in obstructive jaundice. A prospective controlled clinical trial. Lancet 1982;2:896899.

    • Search Google Scholar
    • Export Citation
  • 138.

    Heslin MJ, Brooks AD, Hochwald SN. A preoperative biliary stent is associated with increased complications after pancreatoduodenectomy. Arch Surg 1998;133:149154.

    • Search Google Scholar
    • Export Citation
  • 139.

    Lai EC, Mok FP, Fan ST. Preoperative endoscopic drainage for malignant obstructive jaundice. Br J Surg 1994;81:11951198.

  • 140.

    McPherson GA, Benjamin IS, Hodgson HJ. Pre-operative percutaneous transhepatic biliary drainage: the results of a controlled trial. Br J Surg 1984;71:371375.

    • Search Google Scholar
    • Export Citation
  • 141.

    Pitt HA, Gomes AS, Lois JF. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost? Ann Surg 1985;201:545553.

    • Search Google Scholar
    • Export Citation
  • 142.

    Thomas JH, Connor CS, Pierce GE. Effect of biliary decompression on morbidity and mortality of pancreatoduodenectomy. Am J Surg 1984;148:727-731.

    • Search Google Scholar
    • Export Citation
  • 143.

    Aadam AA, Evans DB, Khan A. Efficacy and safety of self-expandable metal stents for biliary decompression in patients receiving neoadjuvant therapy for pancreatic cancer: a prospective study. Gastrointest Endosc 2012;76:6775.

    • Search Google Scholar
    • Export Citation
  • 144.

    Mullen JT, Lee JH, Gomez HF. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg 2005;9:10941104; discussion 1104–1095.

    • Search Google Scholar
    • Export Citation
  • 145.

    Varadhachary GR, Wolff RA, Crane CH. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:34873495.

    • Search Google Scholar
    • Export Citation
  • 146.

    Varadhachary GR, Wolff RA. The war on pancreatic cancer: are we gaining ground? Oncology 2011;24:13351336.

  • 147.

    Sinn M, Liersch T, Gellert K. CONKO-005: adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—a prospective randomized phase III study [abstract]. J Clin Oncol 2015;33(Suppl):Abstract 4007.

    • Search Google Scholar
    • Export Citation
  • 148.

    Esnaola NF, Chaudhary UB, O'Brien P. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2014;88:837844.

    • Search Google Scholar
    • Export Citation
  • 149.

    Festa V, Andriulli A, Valvano MR. Neoadjuvant chemoradiotherapy for patients with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective studies. JOP 2013;14:618625.

    • Search Google Scholar
    • Export Citation
  • 150.

    Kim EJ, Ben-Josef E, Herman JM. A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer. Cancer 2013;119:26922700.

    • Search Google Scholar
    • Export Citation
  • 151.

    Landry J, Catalano PJ, Staley C. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol 2010;101:587592.

    • Search Google Scholar
    • Export Citation
  • 152.

    Marti JL, Hochster HS, Hiotis SP. Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer. Ann Surg Oncol 2008;15:35213531.

    • Search Google Scholar
    • Export Citation
  • 153.

    Van Buren G 2nd, Ramanathan RK, Krasinskas AM. Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 2013;20:37873793.

    • Search Google Scholar
    • Export Citation
  • 154.

    Katz MH, Shi Q, Ahmad SA. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg 2016:e161137.

    • Search Google Scholar
    • Export Citation
  • 155.

    Katz MH, Crane CH, Varadhachary G. Management of borderline resectable pancreatic cancer. Semin Radiat Oncol 2014;24:105112.

  • 156.

    Artinyan A, Anaya DA, McKenzie S. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer 2011;117:20442049.

    • Search Google Scholar
    • Export Citation
  • 157.

    Breslin TM, Hess KR, Harbison DB. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123132.

    • Search Google Scholar
    • Export Citation
  • 158.

    Evans DB, Rich TA, Byrd DR. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992;127:13351339.

    • Search Google Scholar
    • Export Citation
  • 159.

    Evans DB, Varadhachary GR, Crane CH. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008;26:34963502.

    • Search Google Scholar
    • Export Citation
  • 160.

    Hoffman JP, Weese JL, Solin LJ. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995;169:7177.

    • Search Google Scholar
    • Export Citation
  • 161.

    Hoffman JP, Lipsitz S, Pisansky T. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998;16:317323.

    • Search Google Scholar
    • Export Citation
  • 162.

    Mornex F, Girard N, Delpero JR, Partensky C. Radiochemotherapy in the management of pancreatic cancer-part I: neoadjuvant treatment. Semin Radiat Oncol 2005;15:226234.

    • Search Google Scholar
    • Export Citation
  • 163.

    Palmer DH, Stocken DD, Hewitt H. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007;14:20882096.

    • Search Google Scholar
    • Export Citation
  • 164.

    Quiros RM, Brown KM, Hoffman JP. Neoadjuvant therapy in pancreatic cancer. Cancer Invest 2007;25:267273.

  • 165.

    Spitz FR, Abbruzzese JL, Lee JE. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997;15:928937.

    • Search Google Scholar
    • Export Citation
  • 166.

    Talamonti MS, Small W, Mulcahy MF. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006;13:150158.

    • Search Google Scholar
    • Export Citation
  • 167.

    Pingpank JF, Hoffman JP, Ross EA. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg 2001;5:121130.

    • Search Google Scholar
    • Export Citation
  • 168.

    Tachezy M, Gebauer F, Petersen C. Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749). BMC Cancer 2014;14:411.

    • Search Google Scholar
    • Export Citation
  • 169.

    Reni M. Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J Gastroenterol 2010;16:48834887.

  • 170.

    White RR, Hurwitz HI, Morse MA. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001;8:758765.

  • 171.

    Furman MJ, Lambert LA, Sullivan ME, Whalen GF. Rational follow-up after curative cancer resection. J Clin Oncol 2013;31:11301133.

  • 172.

    Tzeng CW, Fleming JB, Lee JE. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford) 2012;14:365372.

    • Search Google Scholar
    • Export Citation
  • 173.

    Tzeng CW, Abbott DE, Cantor SB. Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis. Ann Surg Oncol 2013;20:21972203.

    • Search Google Scholar
    • Export Citation
  • 174.

    Philip PA, Mooney M, Jaffe D. Consensus report of the National Cancer Institute Clinical Trials Planning Meeting on pancreas cancer treatment. J Clin Oncol 2009;27:56605669.

    • Search Google Scholar
    • Export Citation
  • 175.

    Tempero MA, Berlin J, Ducreux M. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol 2011;22:15001506.

    • Search Google Scholar
    • Export Citation
  • 176.

    Tempero MA, Klimstra D, Berlin J. Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer. Clin Cancer Res 2013;19:538540.

    • Search Google Scholar
    • Export Citation
  • 177.

    Ellis LM, Bernstein DS, Voest EE. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014;32:12771280.

    • Search Google Scholar
    • Export Citation
  • 178.

    Bao Z, Cao C, Geng X. Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysis. Oncotarget 2016;7:76297639.

    • Search Google Scholar
    • Export Citation
  • 179.

    Kaufman B, Shapira-Frommer R, Schmutzler RK. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244250.

    • Search Google Scholar
    • Export Citation
  • 180.

    Domchek SM, Hendifar AE, McWilliams RR. RUCAPANC: an open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation [abstract]. J Clin Oncol 2016;34(Suppl):Abstract 4110.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 1 0 0
Full Text Views 6964 4887 406
PDF Downloads 2304 1693 176
EPUB Downloads 0 0 0